Core Viewpoint - Jiangxi Jindalai Environmental Protection Co., Ltd. plans to invest 30 million RMB in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, aiming to optimize its industrial structure and explore new growth opportunities in the medical robotics sector [2][3][16]. Investment Overview - The investment amount is set at 30 million RMB, with 195.86895 thousand RMB allocated for the subscription of new registered capital and the remaining 28.04131 million RMB added to the capital reserve [3]. - The investment has been approved through internal procedures and does not require further approval from the board or shareholders, nor does it constitute a major asset restructuring or related party transaction [2][4]. Target Company Information - Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems, founded by a team of experts led by Professor Hou Zengguang [5]. - The company has a strong research background, having undertaken significant projects in the vascular interventional surgery robot field since 2008, and holds over 100 independent intellectual property rights [5]. - The target company is recognized as a national high-tech enterprise and has products in the special review process for innovative medical devices by the National Medical Products Administration [5][6]. Financial and Operational Aspects - The investment will be made in cash from the company's own funds, and the funds will be used for technology research and development, market promotion, and daily operations [12][16]. - The target company has completed 16 clinical trials for its multi-channel vascular interventional surgery robot, which is currently in the process of accelerating its clinical trials [6]. Strategic Impact - This investment aligns with the company's strategy to diversify into the healthcare sector, particularly in medical devices and biomanufacturing, enhancing its risk resilience and creating new profit growth points [16]. - The investment is expected to strengthen the company's competitive edge and influence in the market, promoting sustainable development without affecting its daily operations or shareholder interests [16].

Core Viewpoint - Company plans to invest 30 million yuan in Zhongke Hongtai to acquire a 10% stake, aiming to optimize its industrial structure and explore new growth opportunities in the medical robotics sector [2] Group 1: Investment Details - The investment is based on the positive outlook for the development of medical robotics technology and applications in strategic emerging industries [2] - The investment will enhance the company's risk resistance and cultivate new profit growth points [2] Group 2: Zhongke Hongtai Overview - Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems, being a technology transfer enterprise incubated by the Chinese Academy of Sciences [2] - The founding team has undertaken over 10 major projects, including the first domestic "863 Program" for vascular interventional surgical robots since 2008, establishing itself as a pioneer in the field [2] - The company holds over 100 independent intellectual property rights and has participated in the formulation of 2 industry standards [2] Group 3: Product Advantages - Zhongke Hongtai's multi-channel vascular interventional surgical robot features bionic design, allowing simultaneous rotation and pushing of guidewires, and can operate two guidewires and two balloon/stent catheters simultaneously [3] - The robot includes force feedback functionality and can perform remote surgeries, full-process robotic assistance, and data collection [3] Group 4: Clinical Trials and Future Plans - The product requires clinical trials before market registration, with the first patient enrolled in a clinical trial for the world's first multi-channel fully assisted vascular interventional surgical robot on November 25, 2025 [3] - As of the announcement date, 16 clinical trials have been completed, and the company is accelerating progress [3] Group 5: Company Strategy - The company is an advanced innovative comprehensive service provider for water environment governance and plans to invest in non-listed companies in the health sector, including medical devices and biomanufacturing, to optimize its industrial structure [2][3]

Group 1 - *ST Dongyi's restructuring plan has been approved by the court, marking the end of its restructuring process and entering the execution phase, which is expected to improve the company's financial structure and promote sustainable development [1] - Guankang Technology is planning to acquire at least 60% of Liaojing Electronics' shares, leading to a suspension of trading starting December 22, 2025, due to uncertainties surrounding the transaction [2] - Zhuoran Co. and its actual controller are under investigation for suspected violations of information disclosure laws, but the company's operations remain normal during this period [3] Group 2 - China Shenhua plans to issue A-shares and pay cash to acquire assets from its controlling shareholder, with a total transaction value of 133.598 billion yuan, which will significantly enhance its coal resource reserves and production capacity [5] - Bohai Chemical has decided to terminate its major asset restructuring plan due to a lack of agreement on key terms, with trading resuming on December 22, 2025 [6] - Jinshi Resources intends to acquire a 15.7147% stake in Noah Fluorine Chemical for approximately 256.94 million yuan, which will strengthen its position in the fluorine chemical sector [8] Group 3 - Qingdao Port plans to invest 9.097 billion yuan in the construction of a container terminal, with an expected internal rate of return of 8.15% [13] - Tianchuang Fashion is undergoing a potential change in control, leading to a suspension of its stock starting December 22, 2025, for a maximum of two trading days [12] - Deyu Water Conservancy has won a bid for a significant irrigation project in Guangxi, with a contract value of 1 billion yuan, which is expected to positively impact future earnings [15] Group 4 - The stock of Guizhou Bailin will be suspended for one day starting December 22, 2025, due to an administrative penalty notice, and will resume trading under the name "ST Bailin" [20] - *ST Weihai's stock will also be suspended for one day and will resume trading on December 23, 2025, with the removal of certain risk warnings [23] - Tianpu Co. has completed a public offering of shares, with a total of 33.52 million shares being offered at a price of 23.98 yuan per share [21]

Core Viewpoint - Jindalai (688057) plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, indicating a strategic move towards the medical robotics sector [1] Group 1: Investment Details - The investment amount is 30 million yuan, which will be used to increase the capital of Zhongke Hongtai [1] - After the transaction, Jindalai will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Company Strategy - Jindalai expresses optimism about the development prospects of medical robotics technology and systems, which are part of the national strategic emerging industries [1] - The company aims to gradually optimize its industrial structure and seek new opportunities for future growth, enhancing its risk resistance and cultivating new profit growth points [1]

Group 1 - The company, Jindalai, announced plans to invest 30 million yuan of its own funds to increase its stake in Beijing Zhongke Hongtai Medical Technology Co., Ltd. [1] - After the investment, Jindalai will hold a 10.00% equity stake in Beijing Zhongke Hongtai Medical Technology Co., Ltd. [1]

Core Viewpoint - Jindalai (688057.SH) plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, aiming to optimize its industrial structure and seek new growth opportunities [1] Group 1: Investment Details - The investment will be made using the company's own funds amounting to 30 million yuan [1] - After the investment, Jindalai will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Company Background - Zhongke Hongtai specializes in the research, production, and sales of medical robot technology and systems [1] - The company was incubated by the Institute of Automation, Chinese Academy of Sciences, and is led by a team of experts including Professor Hou Zengguang [1] - Since 2008, the founding team has undertaken over 10 major projects, including the first domestic 863 program for vascular interventional surgical robots [1] Group 3: Financial Status and Purpose of Investment - Zhongke Hongtai is currently not profitable [1] - The investment aims to enhance the company's risk resistance and cultivate new profit growth points [1] - Funds from the investment will be allocated for technology research and development, market promotion, and daily operations [1]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to seek new opportunities for growth and enhance its risk resistance [1] Group 1: Investment and Financial Actions - The company plans to invest RMB 30 million in Zhongke Hongtai, with RMB 1.9586895 million allocated for subscribing to the new registered capital of Zhongke Hongtai and the remaining RMB 28.0413105 million to be added to the capital reserve [1] - After the completion of this transaction, the company will hold a 10.00% equity stake in Zhongke Hongtai [1]

证券代码：688057 证券简称：金达莱 公告编号：2025-035 江西金达莱环保股份有限公司 关于自愿披露对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：北京中科鸿泰医疗科技有限公司（以下简称"中科鸿泰"、 "标的公司"） 投资金额：江西金达莱环保股份有限公司（以下简称"公司"、"金达 莱"）拟使用自有资金 3000 万元向中科鸿泰增资，交易完成后公司将持有中 科鸿泰 10.00%的股权 已履行的审议程序：本次对外投资事项已经公司内部审议程序批准， 无需提交董事会、股东会审议通过。本次对外投资不构成《上市公司重大资 产重组管理办法》规定的重大资产重组，亦不构成关联交易。 相关风险提示：标的公司目前尚未盈利，实际经营过程中可能受行业 政策、市场准入、市场推广、运营管理等因素的影响，未来具体经营业绩及 投资收益仍存在不确定性。敬请广大投资者谨慎决策，注意投资风险。 一、对外投资概述 （一）本次交易概况 1、本次交易概况 1 / 7 公司基于对医疗机器人技术与系统的研发及应用等国家战 ...

Core Viewpoint - The company Jindalai (688057) plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake in the company [1] Group 1: Company Overview - Zhongke Hongtai specializes in the research, development, production, and sales of medical robot technology and systems [1] - The company was incubated by the Institute of Automation, Chinese Academy of Sciences, and is led by a team of experts including Professor Hou Zengguang, who has been involved in significant projects since 2008 [1] - Zhongke Hongtai is recognized as a pioneer in the field of vascular interventional surgical robots in China, having undertaken over 10 major projects, including the first domestic 863 program for vascular interventional surgical robots [1] Group 2: Financial Status - Zhongke Hongtai is currently not profitable [1]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a strategic investment in Zhongke Hongtai Medical Technology Co., Ltd. [1] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to capital reserves [1] - Upon completion of the transaction, the company will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular intervention surgical robot features significant advantages, including a bionic design that allows simultaneous rotation and pushing of guidewires [1] - The dual-channel design enables the operation of two guidewires and two balloon/stent catheters simultaneously, along with force feedback functionality [1] - The surgical robot can perform remote surgeries, provide full-process robotic assistance, and collect data, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, and improve overall competitiveness and influence, promoting sustainable development [2]